Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

LUN14-179

A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab (MK-3475) for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179

Status: Closed to Accrual

This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab (MK-3475), following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA or IIIB NSCLC. No randomization or blinding is involved.

  • Condition: Carcinoma, Non-Small Cell Lung
  • Intervention:
    • Drug: Pembrolizumab
  • Phase: Phase 2

For full description, see www.clinicaltrials.gov.

Read news release about this trial.

Watch a video about this trial:

Abstracts/Posters/Presentations:

  • G.A. Durm, E.A. Kio, W.B. Fisher, M.L. Titzer, S.Jabbour, T.Breen, Z.Liu, N.H. Hanna. Phase II trial of consolidation Pembrolizumab following concurrent chemoradiation in patients (pts) with unresectable or inoperable stage III non-small cell lung cancer (NSCLC): initial safety data from HCRN LUN 14-179. Accepted as a publication-only abstract at the ASCO Annual Meeting, June 3-7, 2016, Chicago IL. J Clin Oncol 34, 2016 (suppl; abstr e20025). See abstract.

Project Manager: Dana Musapatika, dmusapatika@hoosiercancer.org; (317) 634-5842, ext. 39.